alaunos.com (TCRT) Cash Funds per Single Share

Symbol and logo of brand Alaunos Therapeutics, Inc. (TCRT)

The prospects for Alaunos Therapeutics (TCRT) are determined by the outcomes of solid tumor tests and liquidity management. The cash per share on the GURU.Markets time chart shows that the metric remains around 0.14. The business relies on the Sleeping Beauty platform with a closed-loop cell modification cycle, yet faces pressure from tech giants capable of scaling their developments more rapidly.

TCRT alaunos.com: Cash per Single Share in the range 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for alaunos.com (TCRT)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:TCRT (Alaunos Therapeutics Inc.)
Finished products of Alaunos Therapeutics

Alaunos Therapeutics (TCRT) is investing in the development of T-cell therapy to combat solid tumors in collaboration with US institutions. Cash per share is defined as the ratio of the total cash balance to the number of outstanding securities. This metric measures internal liquidity, determining the company's ability to fund costly genetic research without equity dilution. It is critical for investors to monitor this balance to assess the risks of frozen funds or readiness for expansion. Analyzing the cash per share allows for the forecasting of the business's long-term sustainability.